Trulicity Alternatives & Comparison
How Trulicity (dulaglutide) compares to Ozempic, Mounjaro, Rybelsus — mechanism, trial weight-loss results, and cost — plus where to compare vetted providers.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Trulicity Alternatives Compared
Once-weekly GLP-1 with generally greater A1c and weight reduction at matched doses
Ozempic activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, and reduce blood sugar levels.
Ozempic (semaglutide) is the stronger T2D molecule head-to-head: SUSTAIN-7 at 40 weeks showed Ozempic 1 mg dropped A1C 1.8% and weight 6.5 kg, vs Trulicity 1.5 mg's 1.4% A1C and 3.0 kg. Both have FDA-approved cardiovascular indications, but the trials differ — SUSTAIN-6 showed Ozempic cut MACE 26% in a secondary-prevention cohort, while REWIND showed Trulicity cut MACE 12% across a larger primary-prevention population. Trulicity wins on pediatric labeling (ages 10+) and advanced kidney disease (AWARD-7). Both are weekly injections, T2D-only labels.
Full Ozempic vs Trulicity comparison →Dual GIP/GLP-1 mechanism, typically the strongest glycemic and weight effect in this class
Mounjaro's tirzepatide activates both GIP and GLP-1 receptors — making it a "dual agonist" or "twincretin." For diabetes, this dual action powerfully lowers blood sugar by increasing insulin secretion and reducing glucagon.
Mounjaro (tirzepatide) is Lilly's successor to Trulicity (dulaglutide) and outperforms it on every glycemic and weight axis — SURPASS-2 and SURPASS-3 placed Mounjaro 15 mg at ~2.3% A1C reduction and ~12 kg weight loss vs Trulicity 1.5 mg's roughly 1.1% A1C drop and ~3 kg in legacy AWARD trials. Trulicity holds three niche advantages: a proven cardiovascular outcome benefit (REWIND, MACE −12%), a pediatric T2D indication (ages 10+), and renal-impairment evidence from AWARD-7. Mounjaro's SURPASS-CVOT reads out in 2027.
Full Mounjaro vs Trulicity comparison →Oral daily GLP-1 for patients who prefer to avoid a weekly injection
Rybelsus delivers semaglutide — a GLP-1 receptor agonist — in tablet form by co-formulating each pill with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption enhancer that transiently raises gastric pH and helps the semaglutide peptide cross the gastric mucosa intact before stomach acid and proteases can degrade it.
Rybelsus and Trulicity are both FDA-approved for type 2 diabetes only — neither is labeled for chronic weight management. Rybelsus 14 mg drops A1C roughly 1.0-1.4% but requires a daily empty-stomach ritual: one tablet with no more than 4 oz of plain water, then a 30-minute fast. Trulicity 1.5 mg drops A1C 1.1-1.4% as a once-weekly subcutaneous injection with no food restriction and a proven 12% MACE reduction from REWIND. Trulicity also has a pediatric indication (≥10 years); Rybelsus is adults-only. Pick by tolerance for daily fasting versus weekly needles.
Full Rybelsus vs Trulicity comparison →Compare compounded Semaglutide providers
Compounded semaglutide runs a median of $199/month across 251 vetted-provider price points (range $65–$599). Featured partners below, ranked by our partner-economics ordering.
Compare compounded Tirzepatide providers
Compounded tirzepatide runs a median of $275/month across 219 vetted-provider price points (range $99–$1,100). Featured partners below, ranked by our partner-economics ordering.
Compare every Trulicity provider
See current pricing, verification status, form, and states served across every vetted provider in one place.